RESUMEN
The Taiwan Headache Society published its guidelines for acute migraine treatment in 2017. Since then, emerging drugs and treatment options have developed rapidly. The migraine-specific drugs gepants and ditans and several noninvasive neuromodulation devices have been approved for use in Europe and the United States. Although not all emerging drugs and treatment options have been approved for use in Taiwan, keeping pace with international trends and updating treatment guidelines are imperative. Therefore, the Treatment Guideline Subcommittee of the Taiwan Headache Society reviewed the quality of recent trials, evaluated the corresponding grade of evidence, and appraised the reported clinical efficacy to reach a new consensus. To ensure that the updated Taiwan guidelines are appropriate and feasible, the subcommittee also referred to the guidelines from the United States, Europe, Canada, and other countries concerning the main roles, recommendation levels, clinical efficacy, and adverse reactions of drugs for the acute migraine treatment. Several types of drugs are currently available for acute migraine treatment in Taiwan. These drugs can be categorized into migraine-specific and migraine-non-specific. Among them, migraine-specific triptans (oral or nasal spray formulations) and migraine-nonspecific acetaminophen and NSAIDs (diclofenac, ibuprofen, naproxen) are highly recommended because they are supported by strong evidence and demonstrate high efficacy. Prochlorperazine injection has been upgraded to a highly recommended level because of the rich clinical experience for this treatment. Ergotamine/caffeine remains a second-line drug because of its lower specificity and efficacy compared with triptans. High-dose aspirin was downgraded to rescue treatment because of potential gastrointestinal side effects. Although evidence supports the combination of oral tramadol and acetaminophen, this combination should be used as a rescue treatment due to concerns about dependence. Evidence supporting the use of intravenous tramadol or morphine is insufficient; therefore, their use is not recommended. As for non-pharmacological approaches, there are only limited controlled data. The choice of treatment for acute migraine attacks should follow the concept of "stratified care." For mild to moderate migraine attacks, oral NSAIDs are the first choice, with combination analgesics, intravenous/intramuscular NSAIDs as alternatives. For moderate to severe attacks, oral or nasal spray triptans and ergotamine/caffeine compounds are recommended and should be administered in the early stage of migraine attacks. Antiemetics can be used as supplements to alleviate nausea and vomiting. Other emerging migraine-specific drugs, such as gepants or ditans, may also have a role in the future. Notably, a combination of a triptan and a NSAID yielded a better efficacy compared with either therapy alone. Parenteral steroids and fluid supply are the first-line treatment for status migrainosus. Acetaminophen is suitable for mild to moderate migraine attacks and remains the first choice for children and pregnant women. To prevent medication overuse headache, the use of acute treatment should be limited to a maximum of 2 days per week. Key words: acute migraine treatment, evidence-based medicine, treatment guidelines, triptans, ergotamine, neuromodulation.
Asunto(s)
Antieméticos , Trastornos Migrañosos , Tramadol , Acetaminofén/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Antieméticos/uso terapéutico , Aspirina/uso terapéutico , Cafeína/uso terapéutico , Antagonistas del Receptor Peptídico Relacionado con el Gen de la Calcitonina/uso terapéutico , Niño , Diclofenaco/uso terapéutico , Femenino , Cefalea/tratamiento farmacológico , Humanos , Ibuprofeno/uso terapéutico , Trastornos Migrañosos/tratamiento farmacológico , Derivados de la Morfina/uso terapéutico , Naproxeno/uso terapéutico , Rociadores Nasales , Embarazo , Proclorperazina/uso terapéutico , Taiwán , Tramadol/uso terapéutico , Triptaminas/uso terapéuticoRESUMEN
Background: Yamamoto New Scalp Acupuncture (YNSA) is a therapy based on the stimulation of points on the scalp and applied to treat different states of pain. Objectives: To investigate the analgesic efficacy of YNSA for dogs undergoing radical unilateral mastectomy with ovariohysterectomy. Methods: Twenty-four dogs were randomly distributed into two treatments (n = 12, per group): bilateral stimulation of basic B, D, and E points (YNSA group) and no application of acupuncture (control group). All dogs were sedated with morphine; anesthesia was induced with propofol and maintained with isoflurane. Fentanyl was intraoperatively administered to control cardiovascular responses to surgical stimulation. Postoperative pain was assessed using an interactive visual analog scale (IVAS) and the short-form of the Glasgow Composite Pain Scale (CMPS-SF). Morphine was administered as rescue analgesia. Data were analyzed using t-tests, Fisher's exact test, Mann-Whitney U test, and Friedman test (p < 0.05). Results: Intraoperatively, the number of dogs requiring supplemental analgesic and the number of doses of fentanyl were lower in the YNSA group than in the control group (p = 0.027-0.034). The IVAS pain scores recorded from 0.5 h to 1 h post-extubation in the YNSA group were lower than those in the control group (p = 0.021-0.023). Postoperative rescue analgesia and CMPS-SF pain scores did not differ between the groups. Conclusion: YNSA decreases intraoperative fentanyl requirements and provides minimal postoperative analgesic benefits to dogs undergoing unilateral mastectomy with ovariohysterectomy.
Asunto(s)
Terapia por Acupuntura , Cuero Cabelludo , Animales , Perros , Femenino , Humanos , Analgésicos/uso terapéutico , Fentanilo/farmacología , Fentanilo/uso terapéutico , Histerectomía/veterinaria , Mastectomía , Derivados de la Morfina/uso terapéutico , Ovariectomía/veterinaria , Dolor Postoperatorio/tratamiento farmacológico , Dolor Postoperatorio/veterinaria , Cuero Cabelludo/cirugíaRESUMEN
OBJECTIVES: To describe the association between exposure to selected complementary and integrative health (CIH) modalities and the trajectory of prescribed opioid analgesic dose within a national cohort of patients receiving long-term opioid therapy (LTOT) in the Veterans Health Administration (VHA). MATERIALS AND METHODS: Using national data from VHA electronic health records between October 1, 2017 and September 30, 2019, CIH use was analyzed among 57,437 patients receiving LTOT within 18 VHA facilities serving as evaluation sites of VHA's Whole Health System of Care. Using linear mixed effects modeling controlling for covariates, opioid dose was modeled as a function of time, CIH exposure, and their interaction. RESULTS: Overall, 11.91% of patients on LTOT used any of the focus CIH therapies; 43.25% of those had 4 or more encounters. Patients used acupuncture, chiropractic care, and meditation modalities primarily. CIH use was associated with being female, Black, having a mental health diagnosis, obesity, pain intensity, and baseline morphine-equivalent daily dose. Mean baseline morphine-equivalent daily dose was 40.81 milligrams and dose decreased on average over time. Controlling for covariates, patients with any CIH exposure experienced 38% faster dose tapering, corresponding to a mean difference in 12-month reduction over patients not engaging in CIH of 2.88 milligrams or 7.06% of the mean starting dose. DISCUSSION: Results support the role of CIH modalities in opioid tapering. The study design precludes inference about the causal effects of CIH on tapering. Analyses did not consider the trend in opioid dose before cohort entry nor the use of other nonopioid treatments for pain. Future research should address these questions and consider tapering-associated adverse events.
Asunto(s)
Dolor Crónico , Terapias Complementarias , Veteranos , Analgésicos Opioides , Dolor Crónico/terapia , Estudios de Cohortes , Terapias Complementarias/métodos , Femenino , Humanos , Masculino , Derivados de la Morfina/uso terapéuticoRESUMEN
BACKGROUND: Morphine-6-O-sulfate (M6S) is a mixed µ/δ-opioid receptor (OR) agonist and potential alternative to morphine for treatment of chronic multimodal pain. METHODS: To provide more support for this hypothesis, the antinociceptive effects of M6S and morphine were compared in tests that access a range of pain modalities, including hot plate threshold (HPT), pinprick sensitivity threshold (PST) and paw pressure threshold tests. RESULTS: Acutely, M6S was 2- to 3-fold more potent than morphine in HPT and PST tests, specifically, derived from best-fit analysis of dose-response relationships of morphine/M6S half-effective dose (ED50) ratios (lower, upper 95% confidence interval [CI]) were 2.8 (2.0-5.8) in HPT and 2.2 (2.1, 2.4) in PST tests. No differences in analgesic drug potencies were detected in the PPT test (morphine/M6S ED50 ratio 1.2 (95% CI, 0.8-1.4). After 7 to 9 days of chronic treatment, tolerance developed to the antinociceptive effects of morphine, but not to M6S, in all 3 pain tests. Morphine-tolerant rats were not crosstolerant to M6S. The antinociceptive effects of M6S were not sensitive to κ-OR antagonists. However, the δ-OR antagonist, naltrindole, blocked M6S-induced antinociception by 55% ± 4% (95% CI, 39-75) in the HPT test, 94% ± 4% (95% CI, 84-105) in the PST test, and 5% ± 17% (95% CI, -47 to 59) or 51% ± 14% (95% CI, 14-84; 6 rats per each group) in the paw pressure threshold test when examined acutely or after 7 days of chronic treatment, respectively. CONCLUSIONS: Activity via δ-ORs thus appears to be an important determinant of M6S action. M6S also exhibited favorable antinociceptive and tolerance profiles compared with morphine in 3 different antinociceptive assays, indicating that M6S may serve as a useful alternative for rotation in morphine-tolerant subjects.
Asunto(s)
Analgesia/métodos , Tolerancia a Medicamentos , Derivados de la Morfina/uso terapéutico , Manejo del Dolor/métodos , Dolor/tratamiento farmacológico , Analgésicos Opioides/farmacología , Analgésicos Opioides/uso terapéutico , Animales , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Masculino , Derivados de la Morfina/farmacología , Dolor/patología , Dimensión del Dolor/efectos de los fármacos , Dimensión del Dolor/métodos , Ratas , Ratas Sprague-Dawley , Receptores Opioides delta/agonistas , Receptores Opioides mu/agonistasRESUMEN
BACKGROUND AND PURPOSE: For patients experiencing inadequate analgesia and intolerable opioid-related side effects on one strong opioid analgesic, pain relief with acceptable tolerability is often achieved by rotation to a second strong opioid. These observations suggest subtle pharmacodynamic differences between opioids in vivo. This study in rats was designed to assess differences between opioids in their in vivo profiles. EXPERIMENTAL APPROACH: Male Sprague Dawley rats were given single i.c.v. bolus doses of morphine, morphine-6-glucuronide (M6G), fentanyl, oxycodone, buprenorphine, DPDPE ([D-penicillamine(2,5) ]-enkephalin) or U69,593. Antinociception, constipation and respiratory depression were assessed using the warm water tail-flick test, the castor oil-induced diarrhoea test and whole body plethysmography respectively. KEY RESULTS: These opioid agonists produced dose-dependent antinociception, constipation and respiratory depression. For antinociception, morphine, fentanyl and oxycodone were full agonists, buprenorphine and M6G were partial agonists, whereas DPDPE and U69,593 had low potency. For constipation, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, morphine produced a bell-shaped dose-response curve, whereas DPDPE and U69,593 were inactive. For respiratory depression, morphine, M6G, fentanyl and buprenorphine were full agonists, oxycodone was a partial agonist, whereas DPDPE and U69,593 were inactive. The respiratory depressant effects of fentanyl and oxycodone were of short duration, whereas morphine, M6G and buprenorphine evoked prolonged respiratory depression. CONCLUSION AND IMPLICATIONS: For the seven opioids we assessed, no two had the same profile for evoking antinociception, constipation and respiratory depression, suggesting that these effects are differentially regulated. Our findings may explain the clinical success of 'opioid rotation'. LINKED ARTICLES: This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
Asunto(s)
Analgésicos Opioides/efectos adversos , Analgésicos Opioides/uso terapéutico , Estreñimiento/inducido químicamente , Dolor/tratamiento farmacológico , Insuficiencia Respiratoria/inducido químicamente , Animales , Bencenoacetamidas/efectos adversos , Bencenoacetamidas/uso terapéutico , Buprenorfina/efectos adversos , Buprenorfina/uso terapéutico , Aceite de Ricino , Diarrea/inducido químicamente , Diarrea/tratamiento farmacológico , Encefalina D-Penicilamina (2,5)/efectos adversos , Encefalina D-Penicilamina (2,5)/uso terapéutico , Fentanilo/efectos adversos , Fentanilo/uso terapéutico , Calor , Masculino , Morfina/efectos adversos , Morfina/uso terapéutico , Derivados de la Morfina/efectos adversos , Derivados de la Morfina/uso terapéutico , Oxicodona/efectos adversos , Oxicodona/uso terapéutico , Pirrolidinas/efectos adversos , Pirrolidinas/uso terapéutico , Ratas Sprague-Dawley , Insuficiencia Respiratoria/fisiopatologíaRESUMEN
Morphine-6-glucuronide (M6G) is an active metabolite of morphine that is being developed by CeNeS Pharmaceuticals as an alternative to morphine (the most commonly used opioid) for the management of postoperative pain. M6G is currently undergoing phase III clinical trials in patients with postoperative pain.
Asunto(s)
Analgésicos Opioides/uso terapéutico , Derivados de la Morfina/uso terapéutico , Dolor Postoperatorio/tratamiento farmacológico , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/síntesis química , Analgésicos Opioides/metabolismo , Analgésicos Opioides/farmacocinética , Analgésicos Opioides/farmacología , Analgésicos Opioides/toxicidad , Animales , Ensayos Clínicos como Asunto , Contraindicaciones , Evaluación Preclínica de Medicamentos , Humanos , Derivados de la Morfina/efectos adversos , Derivados de la Morfina/síntesis química , Derivados de la Morfina/metabolismo , Derivados de la Morfina/farmacocinética , Derivados de la Morfina/farmacología , Derivados de la Morfina/toxicidad , Patentes como Asunto , Relación Estructura-ActividadRESUMEN
Mitragynine is a major indole alkaloid isolated from the Thai medicinal plant Mitragyna speciosa that has opium-like properties, although its chemical structure is quite different from that of morphine. We attempted to develop novel analgesics derived from mitragynine, and thus synthesized the ethylene glycol-bridged and C10-fluorinated derivative of mitragynine, MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate]. We hypothesized that a dual-acting mu- and kappa-opioid agonist could produce potent antinociceptive effects with fewer rewarding effects compared with mu agonists. In this study, MGM-9 exhibited high affinity for mu- and kappa-opioid receptors with Ki values of 7.3 and 18 nM, respectively. MGM-9 showed a potent opioid agonistic effect, and its effects were meditated by mu- and kappa-opioid receptor mechanisms in in vitro assays. Subcutaneous and oral administration of MGM-9 produced potent antinociceptive effects in mouse tail-flick, hot-plate, and writhing tests. When administered orally, the antinociceptive effect of MGM-9 was seven to 22 times more potent than that of morphine. The antinociceptive effects of MGM-9 were mediated by both mu- and kappa-opioid receptors. Subcutaneous administration of MGM-9 twice daily for 5 days led to antinociceptive tolerance. In the gastrointestinal transit study, MGM-9 inhibited gastrointestinal transit, but its effect was weaker than that of morphine at equi-antinociceptive doses. Furthermore, MGM-9 induced less hyperlocomotion and fewer rewarding effects than morphine. The rewarding effect of MGM-9 was blocked by a mu antagonist and enhanced by a kappa antagonist. Taken together, the results suggest that MGM-9 is a promising novel analgesic that has a stronger antinociceptive effect and weaker adverse effects than morphine.
Asunto(s)
Umbral del Dolor/efectos de los fármacos , Dolor/tratamiento farmacológico , Receptores Opioides kappa/agonistas , Receptores Opioides mu/agonistas , Recompensa , Alcaloides de Triptamina Secologanina/farmacología , Analgésicos Opioides/farmacología , Análisis de Varianza , Animales , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Vías de Administración de Medicamentos , Tolerancia a Medicamentos , Tránsito Gastrointestinal/efectos de los fármacos , Cobayas , Masculino , Ratones , Morfina/uso terapéutico , Derivados de la Morfina/uso terapéutico , Dolor/clasificación , Dolor/etiología , Dimensión del Dolor/efectos de los fármacos , Unión Proteica/efectos de los fármacos , Tiempo de Reacción/efectos de los fármacos , Alcaloides de Triptamina Secologanina/química , Alcaloides de Triptamina Secologanina/uso terapéutico , Factores de TiempoRESUMEN
Effects of naloxone, nalorphine, thyroliberin, morphine and two analogues of enkephalins (FK 33-824 and Tyr-D-Ala-Gly-Phe(NO2)-NH2) on the course of traumatic shock were studied in experiments on rabbits. It was found that antagonists of opioid peptides aggravated the course of traumatic shock and morphine and synthetic analogues of enkephalins exerted positive effects during its treatment. Endogenous opioid peptides are suggested to play the protective role in experimental traumatic shock.
Asunto(s)
Encefalinas/uso terapéutico , Derivados de la Morfina/uso terapéutico , Antagonistas de Narcóticos/uso terapéutico , Choque Traumático/tratamiento farmacológico , Animales , Evaluación Preclínica de Medicamentos , Encefalinas/antagonistas & inhibidores , Masculino , Derivados de la Morfina/antagonistas & inhibidores , Nalorfina/uso terapéutico , Naloxona/uso terapéutico , Conejos , Choque Traumático/fisiopatología , Hormona Liberadora de Tirotropina/uso terapéuticoRESUMEN
Postoperative pain and rehabilitation parameters were compared in groups of patients with or without transcutaneous electric nerve stimulation (TENS) after orthopedic surgery. There was a subjective improvement, but only a non significant difference in opiate requirements with the use of TENS postoperatively; rehabilitation parameters turned out to be of limited value in evaluating its effect. Two patients had an allergic reaction after the use of TENS for postoperative pain relief.
Asunto(s)
Terapia por Estimulación Eléctrica , Dolor Postoperatorio/terapia , Estimulación Eléctrica Transcutánea del Nervio , Estudios de Evaluación como Asunto , Humanos , Articulación de la Rodilla/cirugía , Derivados de la Morfina/uso terapéutico , Ácidos Nicotínicos/uso terapéuticoRESUMEN
As revealed, in acute experiments on rabbits, cats, and rats, a new morphine-like synthetic analgesic drug azidomorphine exceeded 20--100-fold the morphine ability to inhibit synaptic transmission in the thalamic structures, cerebral cortex, and the spinal cord during the nociceptive stimulation, and also by its analgesic activity.